Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.272 EUR | +0.38% |
|
+1,961.78% | +1,757.39% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company has insufficient levels of profitability.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1,757.39% | 18.92M | - | ||
+35.14% | 51.51B | B- | ||
-7.43% | 39.03B | B | ||
+34.86% | 38.91B | A | ||
-10.62% | 26.68B | C | ||
+11.63% | 26.13B | B- | ||
-17.77% | 19.91B | B | ||
+40.52% | 13.71B | B+ | ||
+30.70% | 12.38B | C+ | ||
-3.41% | 11.74B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MEIP Stock
- MMI0 Stock
- Ratings MEI Pharma, Inc.